Fig. 3From: Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter studya Overall survival: total doses ≥ 42 Gy versus < 42 Gy group; b progression-free survival: total doses ≥ 42 Gy versus < 42 Gy group; c overall survival: fractions = 3 versus ≥ 4–6 fractions group; d progression-free survival: fractions = 3 versus ≥ 4–6 fractions groupBack to article page